LearnGlossaryMarketStocksSuperinvestorsSign in

AORT

Artivion, Inc.

Healthcare · $1.2B market cap

Verdict

We can't put a fair value on AORT right now. It lost money in at least 2 of its last 3 years, so one year of cash flow isn't a reliable base to value it on.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth-5.5% a year✗
Equity per share growth6.9% a year✗
Sales growth8.9% a year✗
Free cash flow growth-1.9% a year✗
Return on invested capital2.8%✗

Follow AORT

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds AORT. In Q2 2026, 1 added. Who we track

First Eagle Investment Management

First Eagle Investment Management · as of Q2 2026

$7.8M

346,573 shares

Moves in Q2 2026

Added: First Eagle Investment Management

Insider activity

Since Sep 2, 2026: no open-market purchases and 3 sales worth $503K. Why purchases matter

Sales

GREEN ANDREW M

SVP, Regulatory and Quality · 2026-09-10

Sold

$287K

GREEN ANDREW M

SVP, Regulatory and Quality · 2026-09-03

Sold

$39K

GREEN ANDREW M

SVP, Regulatory and Quality · 2026-09-02

Sold

$177K

About Artivion, Inc.

Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in…

Medical - Devices

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works